Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Promising combinations being explored for IDH1 & IDH2-mutated AML

Eytan Stein • 16 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses potential combination therapies for treating IDH1 and IDH2-mutated acute myeloid leukemia (AML). He emphasizes the potential benefits of pairing IDH inhibitors with intensive chemotherapy, menin inhibitors, or FLT3 inhibitors. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Eytan Stein

Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wang et al. • 18 Sep 2026
Outcomes of patients with R/R AML after menin inhibitor failure
0:41
Outcomes of patients with R/R AML after menin inhibitor failure
Eytan Stein • 12 Jun 2026
Revumenib plus IC in newly diagnosed NPM1-mutated AML: REVEAL-ND NPM1 trial-in-progress
0:50
Revumenib plus IC in newly diagnosed NPM1-mutated AML: REVEAL-ND NPM1 trial-in-progress
Eytan Stein • 12 Jun 2026
First-in-human study of the oral CLK inhibitor BH-30236 in adults with R/R AML or HR-MDS
0:55
First-in-human study of the oral CLK inhibitor BH-30236 in adults with R/R AML or HR-MDS
Eytan Stein • 12 Jun 2026

Related Videos

Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
Choosing between fixed-duration and continuous BTK inhibitor therapy in newly diagnosed CLL
1:35
Choosing between fixed-duration and continuous BTK inhibitor therapy in newly diagnosed CLL
Marta Coscia • 16 Oct 2026
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals